Clinical Trial Update: Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating thalidomide in combination with R-CHOP for newly diagnosed, untreated double-expressor diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Fudan University | Conditions: Thalidomide | Phase 3 | Status: UNKNOWN